Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(55)

カスタマーフィードバック(12)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 M{PiOGN6fG:2b4jpZ{BCe3OjeR?= M{LlUlExKG6P MYC3NkBp M1nsU2ROW09? NVfiUWJUWG:2ZX70bYF1\XNiY3HtdJRwfGinY3nuMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M1zjWlI1QTByOEez
HT-29 MU\DfZRwfG:6aXOgRZN{[Xl? MXexNEBvVQ>? M1vjdlczKGh? MoC0SG1UVw>? M4TaVHBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MXqyOFkxODh5Mx?=
HT-29 MkHmR5l1d3SxeHnjJGF{e2G7 MoTFNVAhdk1? NGXt[3g4OiCq NULnWYtHTE2VTx?= NXu2[W8zWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? Mo\ENlQ6ODB6N{O=
PC3 MYHLbY5ie2ViQYPzZZk> MX[xNFAhdk1? NH3zRYUyKGh? M1m0fWROW09? MlHzVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= NGjTdFkzOTl5OE[4Ny=>
PC3 MVrLbY5ie2ViQYPzZZk> NYnufWlTOTByIH7N MoTlNUBp M1LYd2ROW09? NFzkcYdFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= M2DadVIyQTd6Nkiz
PC3 NXTkRodoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP5PHNEOS53IN88US=> M2\R[|EhcA>? MkPnSG1UVw>? NXK3coJmUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N MkTUNlE6Pzh4OEO=
HEK293 M4LNRmZ2dmO2aX;uJGF{e2G7 M4rMSFExOCCwTR?= NH3HcVc5KGh? NH3lWolFVVOR NV\6T3kyUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MlPWNlE2Ozl|MEG=
BT-20 NHPsb5ZMcW6jc3WgRZN{[Xl? NYjwRZR[OjBizszN NFfWT|ZFVVOR Moj1SI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? MXyyNVM2OzV3MR?=
U937 M2G0bGFvfGmkYXP0[ZJq[WxiQYPzZZk> M2DlWlUxKM7:TR?= M2jGXlQ5KGh? M2jXTmROW09? MkLVTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NEPmc|kzOTF2MkGwOi=>
U937 NH3CU4dCdnSrYnHjeIVzcWGuIFHzd4F6 MYi1NEDPxE1? NWXROmRGPDhiaB?= NHTPRnJFVVOR NXfFN2NOTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NVrJTnlQOjFzNEKxNFY>
U937 NX\qcYtMSW62aXLhZ5RmemmjbDDBd5NigQ>? MkfNOVAh|ryP M3vtd|Q5KGh? NUfqWZpxTE2VTx?= Moi4SI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> M1zNdFIyOTR{MUC2
MCF-7 M3TZPGF2fG:yaHHnfUBCe3OjeR?= MnzNN|Ahdk1? Mly3OEBp M33xSGROW09? NWXXTZNKUW6mdXPld{BifXSxcHjh[5k> NHjn[I8zODB{OEGzOC=>
U87MG NIjlNHpMcW6jc3WgRZN{[Xl? MYSxJO69VQ>? M3jM[|YhcA>? M4DEU2ROW09? NH\GcFVRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= MWOxPVg1QDRyNB?=
U87MG NV7YOHNQU2mwYYPlJGF{e2G7 MU[xJO69VQ>? Mm\HOkBp M3q5O2ROW09? M2jEVnBwfGWwdHz5JIlvcGmkaYTzJFRGSlBzKGS3NEkheGixc4Doc5J6dGG2aX;u MYWxPVg1QDRyNB?=
U87MG M3;wUGtqdmG|ZTDBd5NigQ>? MW[xJO69VQ>? MnX0OkBp NYn1dHRoTE2VTx?= MXzEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NHzGeGEyQTh2OESwOC=>
U87MG Mn:xT4lv[XOnIFHzd4F6 MnLuNUDPxE1? NVLMe|VpPiCq NGflWoZFVVOR M2\6UmRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? MlzqNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb M{W1WWF2fG:yaHHnfUBCe3OjeR?= MoTsNE4zKM7:TR?= MXqyOEBp MkXGSG1UVw>? MofOTY5lfWOnczDheZRweGijZ4m= NXfxepV2OTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NFLiSI1CfXSxcHjh[5khSXO|YYm= Mk\wNE4zKM7:TR?= MVKyOEBp MWXEUXNQ Mn;DTY5lfWOnczDheZRweGijZ4m= NUnNWFh[OTh|OUG5OFk>
H4 NVWxO|FwTnWwY4Tpc44hSXO|YYm= Mn;kNE4zKM7:TR?= NYH2SFM{OjRiaB?= MV;EUXNQ MXTJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz NGr5U40yQDB{NEW4OC=>
HeLa M3XZeGZ2dmO2aX;uJGF{e2G7 NW\NToJuOTByIH7N MnzHN|YhcA>? M1LMc2ROW09? M2fzT2lv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NH3odnIyPzV4M{O4OS=>
HeLa MUDGeY5kfGmxbjDBd5NigQ>? NWPvSW5KOTByIH7N NGrGWlc{PiCq Mn;JSG1UVw>? MmfyTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MkWyNVc2PjN|OEW=
HeLa Mn\pSpVv[3Srb36gRZN{[Xl? M1G1cVExOCCwTR?= NEXnN4M{PiCq M{DRTGROW09? MnvmTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NGjrZVQyPzV4M{O4OS=>
SYF MmDKSpVv[3Srb36gRZN{[Xl? MXqxNFAhdk1? NWjPVW1ROjRiaB?= MoXKSG1UVw>? NGeyRZpKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> Ml7ONVc2PjN|OEW=
SYF MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImwS2UyODBibl2= M4LrTlI1KGh? M3jlSmROW09? NXTJTJI1UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> MWGxO|U3OzN6NR?=
HEK293T M4flXWFvfGm4aYLhcEBCe3OjeR?= NYD4cJhFOSCwTR?= NWj6XFhHPCCm MWrEUXNQ Mly3TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= MXGxO|Q5PTVyMR?=
HEK293T MkjaRY51cX[rcnHsJGF{e2G7 NXX0U49QOSCwTR?= M1;NUFQh\A>? M3;5dWROW09? M1PyNWlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSC[NDD3bZRpKEWFNUCgc4YhOC5|IH7N MnK5NVc1QDV3MEG=
PBMC M3PHbWZ2dmO2aX;uJGF{e2G7 MorQNUBvVQ>? M3exdlE1KGR? MYnEUXNQ M3nqbHJm\HWlZYOgR2NTPSCmZX7zbZR6 NH7wflIyPzR6NUWwNS=>
PBMC NUfhToZOTnWwY4Tpc44hSXO|YYm= M2nMTlEhdk1? NWjSdI9WOTRiZB?= NELHc4ZFVVOR NUPZOoI5TG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? M3nLVFE4PDh3NUCx
HEK293 cells MoXET4lv[XOnIFHzd4F6 M1j3NFUxKG6P MWW0OUBucW5? MonWSG1UVw>? NEfGRXZKdmirYnn0d{BuXE:UIHvpcoF{\SCjY4Tpeol1gSC5aYToJGlEPTBib3[gNE4yKG6P NVf5UWRMOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MlyzSpVv[3Srb36gRZN{[Xl? MUexNFAhdk1? M1v0NlQhcA>? NHzDZXFFVVOR MYTJcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> M1nnUVE4OTJ6Mk[y
Human mixed lymphocyte Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITLcno2KG6P NG\uUlBFVVOR M{P0T2lEPTB;MT62JI5ONg>? MnjFNVYyQDV6NkW=
Lewis rat lymph node cells NFLWb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjpSZhCPSEQvF2= NVv4cIhVTE2VTx?= NYXCO5pqUUN3ME2yMlYh|ryP MkLRNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfXd2JROTBibl2= MofvO|IhcA>? MVnEUXNQ MWPJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P NETJcJYyODB{MUm0PC=>
MRK-nu-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwOES1JJBO Mlf1V2FPT0WU
OCUB-M NIfZ[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTVwMkSgdG0> Mli4V2FPT0WU
SF539 NG\hV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLuTWM2OD1zMT62JJBO M1vsdnNCVkeHUh?=
ES4 NWnObId2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwOmVKSzVyPUKxMlUheE1? M2SzUHNCVkeHUh?=
RL95-2 M2fOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn72TWM2OD1zMEegdG0> NIj3bppUSU6JRWK=
LC-2-ad MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6we3NvUUN3ME20NlMheE1? MYHTRW5ITVJ?
Daudi MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjrVItxUUN3ME20N|QheE1? NH2wNmpUSU6JRWK=
NTERA-S-cl-D1 M{TVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfvNZVKSzVyPUS0N{BxVQ>? NYTBNmFxW0GQR1XS
OS-RC-2 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\OSWlEPTB;NkWyJJBO MnjSV2FPT0WU
VA-ES-BJ NUHxSm1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7ofIRKSzVyPUeyN{BxVQ>? MYjTRW5ITVJ?
GR-ST M2HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P1Z2lEPTB;OES2JJBO NXXrWWxCW0GQR1XS
SW872 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjWTWM2OD16NE[gdG0> MXrTRW5ITVJ?
NOS-1 M4LjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnkTWM2OD16N{GgdG0> MVjTRW5ITVJ?
MC116 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVTWM2OD17OEWgdG0> M2jFNHNCVkeHUh?=
NCI-H1355 NFjMS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHBO2tNUUN3ME2xMlAyKG6P NWmydoVIW0GQR1XS
RPMI-8226 NEC2d|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KxWWlEPTB;MT6xPUBvVQ>? MYjTRW5ITVJ?
TE-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC5VHhyUUN3ME2xMlM3KG6P NVjETWs2W0GQR1XS
Ramos-2G6-4C10 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTifWZKSzVyPUGuOFYhdk1? NUjoT4dNW0GQR1XS
KU812 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7nTWM2OD1{LkCxJI5O NWfme3NxW0GQR1XS
EW-1 NIXlOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTxdZdKSzVyPUKuNVchdk1? MnLwV2FPT0WU
KS-1 NGLWc|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS3d5A1UUN3ME2yMlQ2KG6P NF\VSZRUSU6JRWK=
SK-LMS-1 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLsTWM2OD1{LkS5JI5O MmrsV2FPT0WU
TGBC1TKB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTJTWM2OD1{Lk[5JI5O NInqPWJUSU6JRWK=
TE-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml35TWM2OD1{Lke3JI5O NWTVOZljW0GQR1XS
ETK-1 NVTiTpBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwOEKgcm0> M37EOXNCVkeHUh?=
BE-13 NEnsfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHaVGpKSzVyPUKuPVkhdk1? NHjvO2NUSU6JRWK=
A3-KAW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3oVIdKSzVyPUKuPVkhdk1? MmXqV2FPT0WU
TE-10 NIDNWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG3WWRKSzVyPUOuN{BvVQ>? M2rJcHNCVkeHUh?=
DOHH-2 M4HY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwM{Wgcm0> Mk\4V2FPT0WU
ES6 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fFUmlEPTB;Mz60N{BvVQ>? MmDZV2FPT0WU
OPM-2 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TibmlEPTB;ND6xOUBvVQ>? M3vMcXNCVkeHUh?=
SH-4 M2fQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwM{Sgcm0> NIfzSXRUSU6JRWK=
NB13 NHrifHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\OXHdRUUN3ME20MlM3KG6P M3XI[HNCVkeHUh?=
HUTU-80 MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTiV2QxUUN3ME20MlQzKG6P NUHzWWRSW0GQR1XS
CCRF-CEM MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCxTWM2OD12Lkm0JI5O M3P5SnNCVkeHUh?=
TGBC24TKB M1jMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnXZWx{UUN3ME21MlUyKG6P MoezV2FPT0WU
697 NWrHO5NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwMkigcm0> NGrDXWtUSU6JRWK=
J-RT3-T3-5 NHzyT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UVFBKSzVyPU[uOFYhdk1? M4\4R3NCVkeHUh?=
KALS-1 NH\N[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPiTWM2OD14LkW2JI5O Mn\0V2FPT0WU
no-10 M3zB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLrXY44UUN3ME23MlI6KG6P MU\TRW5ITVJ?
SK-NEP-1 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRThwN{mgcm0> NWLRUlZmW0GQR1XS
L-540 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\S[FdWUUN3ME2xNE41OiCwTR?= NHezRnhUSU6JRWK=
JiyoyeP-2003 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2eGhKSzVyPUGwMlk1KG6P MUnTRW5ITVJ?
HH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HKcmlEPTB;MUGuN|khdk1? NX7BOIVVW0GQR1XS
SR M3vWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P3RmlEPTB;MUGuOFUhdk1? MUDTRW5ITVJ?
QIMR-WIL M13rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jOGlEPTB;MUGuPFUhdk1? MkW0V2FPT0WU
A4-Fuk NVH4V4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\CO4FKSzVyPUGzMlEzKG6P NHn0OJpUSU6JRWK=
CESS Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3pbmxEUUN3ME2xN{4yOyCwTR?= MV3TRW5ITVJ?
KE-37 M4OxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD3TWtCUUN3ME2xOk4xPyCwTR?= M2D1WXNCVkeHUh?=
SK-UT-1 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfHZmhKSzVyPUG2MlgyKG6P M1HSe3NCVkeHUh?=
SIG-M5 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF5LkK1JI5O MWLTRW5ITVJ?
HT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TI[WlEPTB;MUeuOkBvVQ>? NELWNGJUSU6JRWK=
DEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsXIJKSzVyPUG3Mlk6KG6P NXLKTpNSW0GQR1XS
SK-PN-DW NI\2emhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPBTWM2OD1{MD6yN{BvVQ>? NUnFcWtGW0GQR1XS
RPMI-8402 M1KxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TuU2lEPTB;MkGuO|chdk1? NIjLUVVUSU6JRWK=
RPMI-6666 NYW2OoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT6ZXJKSzVyPUK0MlQzKG6P NYi4VVRsW0GQR1XS
NCI-H720 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ3LkSxJI5O NHvjOWpUSU6JRWK=
EW-16 M3Gye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDOTWM2OD1{Nj64O{BvVQ>? NFnu[JdUSU6JRWK=
BL-70 M3;ZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XZXmlEPTB;MkiuN|ghdk1? NXf2O2ZlW0GQR1XS
SF126 NVX5U25YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XFZ2lEPTB;M{CuN|ghdk1? M3zTRXNCVkeHUh?=
BC-1 NVn5e3llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2fIlsUUN3ME2zNU4zPiCwTR?= MVrTRW5ITVJ?
MHH-PREB-1 NYTSWYZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonaTWM2OD1|Mj60OEBvVQ>? MlK4V2FPT0WU
A101D M4\pWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPCe|NKSzVyPUOyMlYzKG6P NXvwZWhvW0GQR1XS
NMC-G1 NVrDb|ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLaSIlKSzVyPUOzMlY4KG6P M4nxTnNCVkeHUh?=
LB1047-RCC NHr1UJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHGfWZKSzVyPUO0MlY6KG6P NIXLU|dUSU6JRWK=
EM-2 M1y1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1|OD61N{BvVQ>? NXzKd|lsW0GQR1XS
COLO-684 NWLjdFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD1TWM2OD1|OT64JI5O M3LZOXNCVkeHUh?=
Becker NHTZPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRzLkC1JI5O MnrsV2FPT0WU
BL-41 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvSeY5KSzVyPUSzMlY3KG6P NX;IeXdzW0GQR1XS
MDA-MB-134-VI M3PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nyUWlEPTB;NESuNFIhdk1? NU[0PVVSW0GQR1XS
L-363 M2e3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe5RW43UUN3ME20OE44OyCwTR?= NFju[GlUSU6JRWK=
ECC4 NGPVfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13aZWlEPTB;NESuO|ghdk1? M4PtbnNCVkeHUh?=
A388 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\nd2Y5UUN3ME20OE45OiCwTR?= NXK1fJJIW0GQR1XS
HEL MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR7Lke5JI5O MlzjV2FPT0WU
RKO NFT4dnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3kTWM2OD13MD6yPUBvVQ>? M1vlXHNCVkeHUh?=
KINGS-1 Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXFRndKSzVyPUWxMlU2KG6P M2\OT3NCVkeHUh?=
EB-3 M2fSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexRppKSzVyPUWyMlY4KG6P MUnTRW5ITVJ?
ARH-77 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTV{Lkigcm0> NHjwb5VUSU6JRWK=
GCIY MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rJeGlEPTB;NUOuOFYhdk1? MmmxV2FPT0WU
NCI-H1304 NEjjR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nhT2lEPTB;NUeuNlIhdk1? NWL5SXNKW0GQR1XS
KARPAS-299 NEXpZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXxTWM2OD14MT64NkBvVQ>? M1yyUHNCVkeHUh?=
IA-LM MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILUTHJKSzVyPU[4MlE{KG6P MV;TRW5ITVJ?
GI-1 Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjmfJdKSzVyPUewMlM6KG6P NVzFV2xuW0GQR1XS
TE-11 NI\0XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;P[GdKSzVyPUe3MlE4KG6P MYjTRW5ITVJ?
LS-411N NF;kVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTd5LkW3JI5O M{XVTnNCVkeHUh?=
no-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHiTWM2OD16Mz6yOEBvVQ>? M4ey[3NCVkeHUh?=
MV-4-11 NGjZXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S4e2lEPTB;OEOuO|Mhdk1? MlPTV2FPT0WU
BV-173 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTh|Lkm3JI5O M4f2RXNCVkeHUh?=
CMK NFOzNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mZndKSzVyPUi0MlE3KG6P NF;TOpBUSU6JRWK=
LC4-1 NEPFU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonrTWM2OD16Nj63NkBvVQ>? NVriWGFsW0GQR1XS
COR-L279 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ewNmlEPTB;OEeuNlUhdk1? Mom3V2FPT0WU
NCI-H209 NX2zbIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTh5LkSxJI5O NEjENGhUSU6JRWK=
Raji MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTh7LkeyJI5O MYHTRW5ITVJ?
LB996-RCC NF\kW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljrTWM2OD17Mz60N{BvVQ>? M4[1UHNCVkeHUh?=
NCI-H526 M{TsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTl|LkW5JI5O NH;yXVNUSU6JRWK=
KGN M375fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTl4LkK5JI5O NX;ZUo5qW0GQR1XS
MOLT-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSwTWM2OD17Nj63PUBvVQ>? MkLGV2FPT0WU
PF-382 NFi5[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzXTWM2OD17Nj63PUBvVQ>? NFnM[GFUSU6JRWK=
BC-3 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTl7LkG4JI5O NWfFSZlUW0GQR1XS
KARPAS-422 NX;QSodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjKT2dQUUN3ME2xNFIvODlibl2= MWrTRW5ITVJ?
SBC-1 M1\DdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PSSWlEPTB;MUC3Mlc2KG6P NYPUeVZsW0GQR1XS
LC-1F M4nkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fi[mlEPTB;MUC4MlA2KG6P NEDXZmVUSU6JRWK=
GB-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\WTWM2OD1zMEmuNFIhdk1? MWDTRW5ITVJ?
SNB75 NGDGfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTFzOT62PUBvVQ>? Mn;YV2FPT0WU
BB65-RCC M1TVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFzOT65N{BvVQ>? MlzZV2FPT0WU
NCI-N87 NV3RO4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;oVmlEPTB;MUKxMlk5KG6P MV3TRW5ITVJ?
IST-MEL1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnOTWM2OD1zMkKuN|ghdk1? NXfYWG1uW0GQR1XS
HOP-62 NUL1THJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH3TWM2OD1zMk[uPFkhdk1? NI\EfI5USU6JRWK=
ACN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF2Nj63OUBvVQ>? NWnFUo5TW0GQR1XS
DMS-114 NYLSZpprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF3MD62O{BvVQ>? NFnqV5FUSU6JRWK=
MLMA M{D5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHyTWM2OD1zNUmuPFghdk1? MVPTRW5ITVJ?
HT-144 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HseGlEPTB;MU[1MlQ{KG6P MYfTRW5ITVJ?
C2BBe1 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF4Nz63OkBvVQ>? NFHWbG5USU6JRWK=
L-428 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTNd21KSzVyPUG3O{44KG6P NHXtZVBUSU6JRWK=
DU-4475 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCwXVBWUUN3ME2xPFcvPjhibl2= M1H4dnNCVkeHUh?=
CP67-MEL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF7OT6zPEBvVQ>? NF3LXINUSU6JRWK=
MEG-01 M2faNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3raU2lEPTB;MkCxMlk3KG6P NU\6eHFqW0GQR1XS
IST-SL2 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnwTWM2OD1{MEiuOlMhdk1? M2HjNXNCVkeHUh?=
ES8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ{NT65OEBvVQ>? NEfGPWlUSU6JRWK=
COLO-800 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ|NT6yPEBvVQ>? M3HZR3NCVkeHUh?=
MFH-ino NHOzZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ|NT64OEBvVQ>? NEnyWYJUSU6JRWK=
OVCAR-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ|Nz6yOEBvVQ>? M1v5TnNCVkeHUh?=
PSN1 M1nNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf6e2p[UUN3ME2yOFIvPzFibl2= NFLGNVlUSU6JRWK=
EW-12 NEPpeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD1{NEOuNUBvVQ>? MXnTRW5ITVJ?
HCC1599 NH3q[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn65TWM2OD1{NkGuOFchdk1? MV7TRW5ITVJ?
SJSA-1 M2rVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojJTWM2OD1{N{GuOFYhdk1? NXrFT5FGW0GQR1XS
ST486 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzCNXhrUUN3ME2yPVYvOTRibl2= NEHqT4lUSU6JRWK=
NOMO-1 M4C5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRPYxKSzVyPUOwNE4zOSCwTR?= MonqV2FPT0WU
MN-60 NEntUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7OTWM2OD1|MEWuN|Ihdk1? MXHTRW5ITVJ?
HCC1187 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3vZpNKSzVyPUOwO{4zPSCwTR?= MoroV2FPT0WU
SW982 NV\mNXZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnX[mdEUUN3ME2zNVQvPzVibl2= M3TtT3NCVkeHUh?=
LB647-SCLC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN{OD63NUBvVQ>? MVfTRW5ITVJ?
HC-1 NGDtPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPXbnlKSzVyPUOzOU42KG6P MVPTRW5ITVJ?
EHEB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;pVWlEPTB;M{O3MlUzKG6P MlGyV2FPT0WU
TUR MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3mzRmlEPTB;M{[zMlk2KG6P M4DVfnNCVkeHUh?=
LU-139 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXsTWM2OD1|N{iuNFIhdk1? M{D4dHNCVkeHUh?=
NB1 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq4OJo2UUN3ME2zPFQvPDVibl2= MVHTRW5ITVJ?
BB30-HNC MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfoPY1KSzVyPUO4PE4{OiCwTR?= MVPTRW5ITVJ?
HAL-01 NI\EN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;MVWhlUUN3ME2zPFkvOjZibl2= M{SzenNCVkeHUh?=
K5 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTRzMT6zO{BvVQ>? MW\TRW5ITVJ?
MZ2-MEL Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW3TWM2OD12MUOuOlQhdk1? NHLkfFVUSU6JRWK=
RXF393 NHS0PXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X3VmlEPTB;NEG2MlQ2KG6P MlTuV2FPT0WU
NCI-H1648 NXT2UnR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37IdmlEPTB;NEG3MlU{KG6P MV\TRW5ITVJ?
TE-12 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzNTWM2OD12M{SuNlYhdk1? MV\TRW5ITVJ?
EoL-1- NH;rNGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR|Nz65PEBvVQ>? M3rRdHNCVkeHUh?=
JAR NWfnXIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnVTWM2OD12M{iuOlIhdk1? MXHTRW5ITVJ?
DSH1 NFvzdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TrfWlEPTB;NEW4MlkyKG6P MX7TRW5ITVJ?
NCI-H187 NV3BenQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq5TWM2OD12NkKuPFEhdk1? NEKwUnJUSU6JRWK=
HCE-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETGcYRKSzVyPUS3O{43PiCwTR?= MXXTRW5ITVJ?
8-MG-BA M1ewfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTV6MT61NkBvVQ>? M{HF[XNCVkeHUh?=
KLE NUDm[XlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnIVno3UUN3ME21PFUvOiCwTR?= M4nLU3NCVkeHUh?=
KNS-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnHOm5NUUN3ME21PFYvQDFibl2= MmLTV2FPT0WU
MSTO-211H NYjtUI9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzhfGhKSzVyPU[wPU44PCCwTR?= M3LCOnNCVkeHUh?=
GDM-1 NFjUc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pNWFEUUN3ME22NVQvODlibl2= MnzsV2FPT0WU
TE-1 NH\i[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTQRYpQUUN3ME22OFYvOTJibl2= NVj5RXp5W0GQR1XS
BT-474 NHT5OZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTETWM2OD14NEeuNFYhdk1? NGfJ[I5USU6JRWK=
KARPAS-45 NGrLb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZ2Nz62JI5O MVHTRW5ITVJ?
MOLT-16 NXTBeJlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTZ2Nz65N{BvVQ>? M3PGO3NCVkeHUh?=
KURAMOCHI NWjyU2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZ3Nz61NUBvVQ>? NYjBdXhFW0GQR1XS
K-562 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vkVGlEPTB;Nk[5MlUyKG6P MnS4V2FPT0WU
EKVX NGH6XlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZ5Mj63NUBvVQ>? M1zjWHNCVkeHUh?=
GAK Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD14N{WuN{BvVQ>? NH3YT25USU6JRWK=
NCI-SNU-5 NUO0UW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\l[oJKSzVyPU[5NE4xOSCwTR?= NX3tcI55W0GQR1XS
NCI-H2126 NYD1RVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zqOWlEPTB;N{K2Mlg4KG6P MnjYV2FPT0WU
CTV-1 NHfFTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTd2ND65JI5O M{HKNHNCVkeHUh?=
SW962 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTd2OD60OEBvVQ>? NHXjTVdUSU6JRWK=
MONO-MAC-6 M1O0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HDU2lEPTB;N{W2Mlk{KG6P M4ex[3NCVkeHUh?=
NCI-H748 NHznPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTd3OD65PUBvVQ>? NYDacVVKW0GQR1XS
NCI-H524 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\pe3lKSzVyPUe4NE44OyCwTR?= MYTTRW5ITVJ?
LS-123 M1\xXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTd7NT62PUBvVQ>? NGDxTZJUSU6JRWK=
NB7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLzTWM2OD16MUSuNVQhdk1? M2PCTnNCVkeHUh?=
LS-1034 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr1N4lzUUN3ME24NlgvQThibl2= Mn7KV2FPT0WU
TE-5 NWrXTGZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTh6Mz61OkBvVQ>? M1TLcnNCVkeHUh?=
A704 NYPibIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjDUYRmUUN3ME24PVkvOTVibl2= M2fsbXNCVkeHUh?=
TK10 NUHM[XBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3abW1KSzVyPUmxOk4xOyCwTR?= MlrkV2FPT0WU
NCI-H345 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDQUGtKSzVyPUm0N{4zOiCwTR?= NVWwOJIyW0GQR1XS
CGTH-W-1 NF3OOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTl2OD6xN{BvVQ>? MXXTRW5ITVJ?
NCI-H510A MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLEOFBKSzVyPUm4OU4yOiCwTR?= MX7TRW5ITVJ?
NCI-H1963 M1PSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnjVZdKSzVyPUGuNFMzQTJizszN NH\xUpNUSU6JRWK=
SCC-3 M3Xadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\OPY1YUUN3ME2xMlA{PDF2IN88US=> NY\pTo9mW0GQR1XS
EW-11 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXRcIJKSzVyPUGuNFg4PDNizszN MlXwV2FPT0WU
CPC-N NGDwcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPQTWM2OD1zLkC4PEDPxE1? MnTIV2FPT0WU
NCI-H1417 NF[2cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jUeWlEPTB;MT6xNlI3KM7:TR?= MojwV2FPT0WU
DG-75 M4\neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DHXGlEPTB;MT6xOlI5PSEQvF2= MXjTRW5ITVJ?
HD-MY-Z MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwMU[0NVYh|ryP NFvjZmpUSU6JRWK=
ATN-1 NUnrfWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrITWM2OD1zLkK2NlA6KM7:TR?= MVHTRW5ITVJ?
KM-H2 NYqwSFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjPYxsUUN3ME2xMlI3PDB6IN88US=> NWHqb5JUW0GQR1XS
NCI-H2081 NXnoeok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHKTWM2OD1zLkK2OlM4KM7:TR?= MXvTRW5ITVJ?
HL-60 MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O5eGlEPTB;MT6yOlk2QSEQvF2= NEHTfplUSU6JRWK=
DB NHPGdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP0emJ[UUN3ME2xMlI4OjR{IN88US=> NVHWUolyW0GQR1XS
NCI-H1522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGe4Z5VKSzVyPUGuNlg5QDdizszN M4XpSXNCVkeHUh?=
AM-38 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwM{C3NkDPxE1? NFHxVnBUSU6JRWK=
NCI-H446 M1jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Txc2lEPTB;MT6zNlEzOSEQvF2= MXPTRW5ITVJ?
SU-DHL-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;le5o5UUN3ME2xMlMzQDBzIN88US=> MVnTRW5ITVJ?
NH-12 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrrTWM2OD1zLkO2N|c1KM7:TR?= NWj4U3J3W0GQR1XS
DMS-79 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnYWnVKSzVyPUGuN|Y5PjZizszN MXzTRW5ITVJ?
NCI-H716 NIfqZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KwdGlEPTB;MT6zPFk5PiEQvF2= Mn6xV2FPT0WU
ML-2 M2nWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFwNEG1Nlkh|ryP NVLlcpdDW0GQR1XS
NB10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Wx[mlEPTB;MT60OlY{OiEQvF2= Ml3GV2FPT0WU
ONS-76 M{n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwNUO1Olkh|ryP MWTTRW5ITVJ?
LOUCY NXuyOIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjSPXRpUUN3ME2xMlU1PjV5IN88US=> NX\IOmtHW0GQR1XS
SCLC-21H Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwNUi1PFIh|ryP Mm\vV2FPT0WU
TGW M1\FXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfnTWM2OD1zLk[zPVc2KM7:TR?= NGTzbZVUSU6JRWK=
LXF-289 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn65TWM2OD1zLkezNlY5KM7:TR?= MXHTRW5ITVJ?
BB49-HNC MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnpTWM2OD1zLkezOVg3KM7:TR?= Mo\TV2FPT0WU
NCI-H747 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK2SoE5UUN3ME2xMlc2OzR4IN88US=> M3HPSnNCVkeHUh?=
LU-165 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPqUIRjUUN3ME2xMlg1QTh4IN88US=> NXjxVGp3W0GQR1XS
OMC-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXV[ZJKSzVyPUGuPVUxPjZizszN M3\SVnNCVkeHUh?=
RCC10RGB MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHuTWM2OD1zLkm1PFE4KM7:TR?= MXjTRW5ITVJ?
SW684 M{LsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwOU[wPVkh|ryP Mn\BV2FPT0WU
TE-8 NEfaU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\lWWlEPTB;Mj6wOVU2QSEQvF2= NYq0UmlEW0GQR1XS
SK-N-DZ MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KyPWlEPTB;Mj6xN|I4PCEQvF2= MkLuV2FPT0WU
EVSA-T MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfkT4tZUUN3ME2yMlE4OzF3IN88US=> NXXuOGNvW0GQR1XS
KASUMI-1 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnpTWM2OD1{LkG4PFE2KM7:TR?= NIPNb|NUSU6JRWK=
NKM-1 M{n3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHzTWM2OD1{LkK1OFczKM7:TR?= MVjTRW5ITVJ?
CAL-148 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XPe2lEPTB;Mj6zN|YyPCEQvF2= NIfLcI1USU6JRWK=
NCI-H64 NFm3U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPmUJRIUUN3ME2yMlM1OjN{IN88US=> NITTU4VUSU6JRWK=
KNS-81-FD NGXFdYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMNHpKSzVyPUKuN|Y3OiEQvF2= MVPTRW5ITVJ?
KM12 M1rW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHNb45KSzVyPUKuOFA5OzlizszN MXzTRW5ITVJ?
SW954 MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwNEe3O|kh|ryP NH\hSZNUSU6JRWK=
NCI-H1395 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XRe2lEPTB;Mj61NlY1PSEQvF2= MV;TRW5ITVJ?
DJM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwNkC2N{DPxE1? NF\0cWxUSU6JRWK=
COLO-668 M13zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTRTWM2OD1{LkiyOlk2KM7:TR?= M13kcnNCVkeHUh?=
NCI-H1436 M3TMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPMNodSUUN3ME2yMlg2PjF3IN88US=> NYPpSVVLW0GQR1XS
LB2241-RCC NGPQXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwOE[4N|kh|ryP MlPXV2FPT0WU
GT3TKB MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnGUGJKSzVyPUKuPFkxPTVizszN NXizbZRbW0GQR1XS
COLO-824 M1fLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvYU5pjUUN3ME2yMlg6PzZ6IN88US=> NFfvTFVUSU6JRWK=
ES1 NVm1XI9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnHTWM2OD1{Lki5PFc6KM7:TR?= NFjz[2FUSU6JRWK=
LB771-HNC NUDSXplKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHrVXVKSzVyPUKuPVA6PDZizszN M{fzdHNCVkeHUh?=
GI-ME-N NWG0cGRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXWS5lSUUN3ME2zMlAxQTB2IN88US=> MYLTRW5ITVJ?
NALM-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3VS|FKSzVyPUOuNFA6OzNizszN MoHTV2FPT0WU
LU-134-A Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr0TlFKSzVyPUOuNFU1OjVizszN MW\TRW5ITVJ?
DMS-153 NXPVNIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xfFVKSzVyPUOuNFU5OjRizszN NE\YNJJUSU6JRWK=
MZ1-PC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiTWM2OD1|LkC5NFc5KM7:TR?= NU\DU|JHW0GQR1XS
NCI-H1155 NH\LNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITtSI9KSzVyPUOuNVE3OSEQvF2= MlTJV2FPT0WU
CAS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXTT3BKSzVyPUOuNVM4ODdizszN M1PKdnNCVkeHUh?=
D-502MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7sTWM2OD1|LkG0N|kh|ryP M3zuWXNCVkeHUh?=
NCI-H2141 NVq2T3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf5bmpKSzVyPUOuNVc1PTJizszN NELsOnhUSU6JRWK=
NB6 M4CwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7oN2ZPUUN3ME2zMlE5OjV7IN88US=> NGTYPZpUSU6JRWK=
NCCIT MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\NTWM2OD1|LkKxPFA6KM7:TR?= MULTRW5ITVJ?
NB69 MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwM{G4PVEh|ryP NXm0UXNDW0GQR1XS
JVM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGTWM2OD1|LkO2OFM{KM7:TR?= NYexN21jW0GQR1XS
K052 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3LTWM2OD1|LkO3PVY5KM7:TR?= NWHnUIJHW0GQR1XS
HCC2157 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\1TWM2OD1|LkWzNlI5KM7:TR?= NUK3SHZWW0GQR1XS
KMOE-2 NXzWRVZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLoZ5ZKSzVyPUOuOVQzPDJizszN MWfTRW5ITVJ?
SF268 M4TkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILnSXpKSzVyPUOuO|E2PTRizszN MUDTRW5ITVJ?
CHP-126 NXTYVJlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;WfJBSUUN3ME2zMlc3PDV6IN88US=> M2O5dHNCVkeHUh?=
CP66-MEL M1fsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwN{mwPVQh|ryP MoPsV2FPT0WU
NCI-H69 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV74blI{UUN3ME20MlAyQTN4IN88US=> M4rjU3NCVkeHUh?=
A253 NF3mflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i2[GlEPTB;ND6wNlExOSEQvF2= M37t[nNCVkeHUh?=
NB14 M2LMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXqTWM2OD12LkGwOFc6KM7:TR?= Mn3nV2FPT0WU
NCI-H1694 NUf4NJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBVnhKSzVyPUSuNVMyOTJizszN NHLkcFBUSU6JRWK=
NCI-H2196 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRwMUexOlkh|ryP NF;2XWdUSU6JRWK=
TE-9 NE\M[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHXTWM2OD12LkG3OVgzKM7:TR?= MXrTRW5ITVJ?
D-283MED M1\kcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXyTWM2OD12LkG4PFQh|ryP M4PJTHNCVkeHUh?=
OCI-AML2 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn4U2Q{UUN3ME20MlE6PDh7IN88US=> NWHLO2l2W0GQR1XS
D-263MG M4XzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;kTWM2OD12LkKyPVYyKM7:TR?= MWfTRW5ITVJ?
MPP-89 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HnOGlEPTB;ND6yO|MxPCEQvF2= MlPTV2FPT0WU
LAMA-84 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFWYF{UUN3ME20MlMxPDJzIN88US=> NVeySIN{W0GQR1XS
LB373-MEL-D Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRwM{[3PFkh|ryP M2f4SXNCVkeHUh?=
UACC-257 M3;0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwM{m1N|Qh|ryP MVrTRW5ITVJ?
MC-CAR NYG1bIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHYNm9LUUN3ME20MlQ{QTlizszN MUjTRW5ITVJ?
COLO-320-HSR NV64dJlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vkPGlEPTB;ND60OFQzPyEQvF2= NUjaVZU6W0GQR1XS
P30-OHK Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTwNWdKSzVyPUSuOlY2QDFizszN M3noVHNCVkeHUh?=
UACC-812 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT3SGFKSzVyPUSuOlkyPjFizszN MUfTRW5ITVJ?
CTB-1 NUPhb|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjFR4hKSzVyPUSuO|E2PTVizszN Mk\kV2FPT0WU
ALL-PO NGruRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\QWGtmUUN3ME20Mlg1ODd5IN88US=> NVnaTGxlW0GQR1XS
SK-MEL-2 NYfqVWxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7me2FKSzVyPUSuPFY6PTVizszN NHfHTHdUSU6JRWK=
TC-YIK NEPDNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZUmlEPTB;ND65O|k1OiEQvF2= M3rjVHNCVkeHUh?=
NCI-H1882 NXLiR2NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTmTWM2OD13LkCyNFAyKM7:TR?= NWX2UFVnW0GQR1XS
MHH-CALL-2 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVwMEWwOFIh|ryP NWH0eJBzW0GQR1XS
U-87-MG NVmzO5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHYO5VCUUN3ME21MlA6PDZ4IN88US=> NHTx[WNUSU6JRWK=
NCI-H1092 NEHIVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjrZ|VNUUN3ME21MlI3PTV3IN88US=> MXjTRW5ITVJ?
TE-441-T MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjmc4tKSzVyPUWuNlc5OiEQvF2= MWXTRW5ITVJ?
SK-MEL-1 NULlXXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTVwMkmwOFQh|ryP NIDmRndUSU6JRWK=
EW-22 M1rCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq5UWpJUUN3ME21MlI6PDZ4IN88US=> MWTTRW5ITVJ?
MZ7-mel MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TWR2lEPTB;NT60NFY6OSEQvF2= NW[xe4tOW0GQR1XS
LP-1 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnLTldKSzVyPUWuOFEzQTFizszN MmnCV2FPT0WU
NCI-SNU-16 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZTWM2OD13Lk[0NFc1KM7:TR?= MVPTRW5ITVJ?
LU-65 NUPzNHc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInsbGVKSzVyPUWuO|Y{PzNizszN NFzTTYpUSU6JRWK=
CW-2 NHnubndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfJfFhsUUN3ME21Mlg2QTV7IN88US=> NFf0T5FUSU6JRWK=
WSU-NHL M4nY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTVwOUWxO|Qh|ryP NHnzSGRUSU6JRWK=
IST-MES1 NH7lWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXIPXhKSzVyPUWuPVU1PDNizszN MYfTRW5ITVJ?
U-266 M4q4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XlOGlEPTB;NT65PFIxOiEQvF2= MnKxV2FPT0WU
TALL-1 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;NTWM2OD14LkG0Olg5KM7:TR?= M{DLfnNCVkeHUh?=
Calu-6 NFTrfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHOV5p[UUN3ME22MlE2OzF4IN88US=> NIS2NXdUSU6JRWK=
MMAC-SF MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTZwMUi1OVYh|ryP M{X4enNCVkeHUh?=
NCI-H82 NVL3SVJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwMkC0PFkh|ryP MXfTRW5ITVJ?
RS4-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\nXFFCUUN3ME22MlI2QDl5IN88US=> NYjXdIdiW0GQR1XS
SNU-C2B NUfu[ZF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;FTWM2OD14LkSwPVY6KM7:TR?= MVLTRW5ITVJ?
BOKU MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPI[I5KSzVyPU[uOFc2QTdizszN NV7Sb|J2W0GQR1XS
C8166 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj5[IpbUUN3ME22MlU2QTF{IN88US=> Mn;yV2FPT0WU
D-247MG NYPyWXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPJd5VKSzVyPUeuNFQ{PDdizszN MXXTRW5ITVJ?
EW-18 MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLCTWM2OD15LkC3NlkzKM7:TR?= M3XSbnNCVkeHUh?=
KG-1 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrRdWp5UUN3ME23MlYzPzN6IN88US=> NYrIfW5wW0GQR1XS
REH M3Tadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;BTWM2OD15Lk[4NVA6KM7:TR?= MYHTRW5ITVJ?
U-698-M NIPSN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTdwOESzNVUh|ryP NUXCVXdNW0GQR1XS
KP-N-RT-BM-1 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD1RmxIUUN3ME23Mlk{ODJ7IN88US=> MVzTRW5ITVJ?
MS-1 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\zeopKSzVyPUeuPVYxPDFizszN M36wRXNCVkeHUh?=
SNU-C1 M1z1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwOUixPVIh|ryP M4rXUnNCVkeHUh?=
SK-MM-2 MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRThwMk[wOlUh|ryP NYHN[3VqW0GQR1XS
LAN-6 NVPaTWVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rDUWlEPTB;OD6zNFAxOSEQvF2= NGSzU3RUSU6JRWK=
NEC8 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;4NGlEPTB;OD6zNFY6OSEQvF2= NVXQd5dHW0GQR1XS
NCI-H1770 NGXPXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRThwM{iwNFIh|ryP MmjrV2FPT0WU
D-336MG NYqwVpdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECzVHNKSzVyPUiuOFAyOTZizszN NEfBeXFUSU6JRWK=
COLO-829 NIPR[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQXpZKSzVyPUiuOFg5PzlizszN NV\YU2V3W0GQR1XS
LS-513 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf2VolKSzVyPUiuOVk2QTlizszN Ml3tV2FPT0WU
YT MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrOeVlKSzVyPUiuOlI1OjdizszN NEPlRXBUSU6JRWK=
EW-24 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRThwN{[1OEDPxE1? M2LReHNCVkeHUh?=
IST-SL1 NHXsSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRThwOE[1OFMh|ryP NXf3SoROW0GQR1XS
CA46 M17kTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwOUWwPVgh|ryP NHLVc|dUSU6JRWK=
NCI-H1838 MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH5Wph3UUN3ME24Mlk5PjB{IN88US=> M4nxbHNCVkeHUh?=
NCI-H719 NVf0XHFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4dmlEPTB;OT6yOVI4QSEQvF2= NVW4elNIW0GQR1XS
HCE-T NYLWcnZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKwTWM2OD17LkOwPFUyKM7:TR?= NHHwTYVUSU6JRWK=
A498 NFvwb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rZPWlEPTB;OT6zOlEzPCEQvF2= M{PPeXNCVkeHUh?=
LB831-BLC NGnJd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOxe5JkUUN3ME25Mlc3PTJzIN88US=> MVLTRW5ITVJ?
SKM-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTlwOEW5OlMh|ryP MoDmV2FPT0WU
THP-1 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLUNZlKSzVyPUmuPVY6OThizszN MkfzV2FPT0WU
SHP-77 NFH4SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyLkSwO{DPxE1? MmXEV2FPT0WU
EW-3 NUHtUVl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFyLk[yPFkh|ryP NXO3bGpLW0GQR1XS
KY821 MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fmTmlEPTB;MUCuO|Y{KM7:TR?= NVLWfIpLW0GQR1XS
NCI-SNU-1 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzLkCyNVch|ryP NU[2Z|VMW0GQR1XS
HCC2218 M2fQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm0fJVKSzVyPUGxMlM6QDZizszN MX\TRW5ITVJ?
IM-9 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrXXoJKSzVyPUGxMlUyODZizszN Mn\4V2FPT0WU
NCI-H889 NUjYR|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\vTWM2OD1zMT61N|E{KM7:TR?= MkjDV2FPT0WU
HDLM-2 NUCxT4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrHPYRKSzVyPUGyMlQyPTlizszN NYDvUmpTW0GQR1XS
LB2518-MEL NWLwcogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF{Lk[4NVUh|ryP NEDCTHVUSU6JRWK=
NCI-H23 NULzeoVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPMR2FQUUN3ME2xN{4zPDJ3IN88US=> Mk\hV2FPT0WU
NB17 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPUTWM2OD1zMz60OVc6KM7:TR?= NU\VbI5QW0GQR1XS
NCI-H322M NV\2TIFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF2LkSwOlgh|ryP NEDLbZdUSU6JRWK=
SUP-T1 NXO5O|Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfFTnB6UUN3ME2xOE41OTNizszN NIrPSW5USU6JRWK=
ES3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\U[4RKSzVyPUG1MlA4ODNizszN M3:zRnNCVkeHUh?=
ES5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jFe2lEPTB;MUWuNFc5PyEQvF2= NIDmTYJUSU6JRWK=
NCI-H1650 M4nlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v3XmlEPTB;MUWuOFk4QSEQvF2= MX3TRW5ITVJ?
NCI-H226 M2jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ywd2lEPTB;MUWuPFc3QCEQvF2= M1fIbXNCVkeHUh?=
COR-L88 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF4LkOxOEDPxE1? NIXUN5VUSU6JRWK=
SCC-15 NVHk[3lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfNTWM2OD1zNj6zPFY6KM7:TR?= MnH5V2FPT0WU
GOTO M2jBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm5TWM2OD1zNj60O|k{KM7:TR?= NFXRZXZUSU6JRWK=
SIMA M2XRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3NZpzUUN3ME2xOk41QDB{IN88US=> M2nyTnNCVkeHUh?=
NCI-H1299 NIrxdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH76W2ZKSzVyPUG3MlE2QTFizszN NH\hbYdUSU6JRWK=
NCI-H1581 NX;EdlVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmzTWM2OD1zNz60NlE6KM7:TR?= Mnr1V2FPT0WU
MHH-NB-11 M2nYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF5Lkm2PFMh|ryP MWjTRW5ITVJ?
MFM-223 NU\5ZnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDW2lEPTB;MUiuNFU{QCEQvF2= MV7TRW5ITVJ?
ES7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;0PGhjUUN3ME2xPE42PDNzIN88US=> NXrsU4tDW0GQR1XS
JVM-3 M{juS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF6LkexO{DPxE1? Mnn6V2FPT0WU
RL M4G2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPidWpDUUN3ME2yNE4{QDhizszN MmXTV2FPT0WU
EC-GI-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTpfI5KSzVyPUKxMlIxPDFizszN NV7CRVdsW0GQR1XS
LNCaP-Clone-FGC NWnxRmIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJzLk[3Olgh|ryP NVLSW2tGW0GQR1XS
IMR-5 NWfnXppIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nReWlEPTB;MkGuPFQ6PCEQvF2= NFPkS5pUSU6JRWK=
KP-N-YS MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDuWGNwUUN3ME2yNU45PzVizszN NX32bVdqW0GQR1XS
Mo-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHRPI83UUN3ME2yNk4zOTh3IN88US=> MX7TRW5ITVJ?
NCI-H128 M{DXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ|LkW4OVMh|ryP M4nicHNCVkeHUh?=
RH-1 NFO4[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELaNIlKSzVyPUKzMlc5PjZizszN M{HhR3NCVkeHUh?=
NCI-H2171 NH\ue|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHVS5NKSzVyPUK0MlI1QDVizszN MkfzV2FPT0WU
RPMI-8866 NWLF[ItJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJ4Lke0NkDPxE1? NX6zPZJyW0GQR1XS
SK-N-FI M4\ENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz2TWM2OD1{Nz6zPFEyKM7:TR?= M13PNXNCVkeHUh?=
LOXIMVI M1u0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTJ5LkiwOVEh|ryP MWDTRW5ITVJ?
P31-FUJ MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILSfFhKSzVyPUOxMlU{PzRizszN M{fzU3NCVkeHUh?=
KMS-12-PE NXnkT3V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInvNFZKSzVyPUS5MlU{ODJizszN M3j5TXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 2年-20℃
6月-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

カスタマーフィードバック (12)


Click to enlarge
Rating
Source Nat Genet, 2014, 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell, 2011, 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res, 2012, 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy, 2015, 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep, 2015, 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol, 2015, 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res, 2011, 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta, 2013, 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis, 2013, 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2011, Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Click to enlarge
Rating
Source 2013, Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

文献中の引用 (55)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ